| Original language | English (US) |
|---|---|
| Pages (from-to) | 6-8 |
| Number of pages | 3 |
| Journal | The Lancet Diabetes and Endocrinology |
| Volume | 10 |
| Issue number | 1 |
| DOIs |
|
| State | Published - Jan 2022 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet Diabetes and Endocrinology, Vol. 10, No. 1, 01.2022, p. 6-8.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Opportunities and challenges in closed-loop systems in type 1 diabetes
AU - Wilson, Leah M.
AU - Jacobs, Peter G.
AU - Riddell, Michael C.
AU - Zaharieva, Dessi P.
AU - Castle, Jessica R.
N1 - Funding Information: LMW has received research support from the Oregon Health & Science University Medical Research Foundation and a speaker's honorarium from the Association of Diabetes Care and Education Specialists. PGJ has received travel honorarium and research support from Dexcom; has received research support and licensing revenue from Agamatrix; has patents issued and pending on continuous glucose monitoring and closed-loop areas; and is on the board of, and owns stock in, Pacific Diabetes Technologies. MCR has served in an advisory role for Zealand Pharma, Zucara Therapeutics, Xeris Pharmaceuticals, and Supersapiens; has received compensation as a speaker at scientific sessions, workshops, or both sponsored by Novo Nordisk, Eli Lilly, Sanofi, Insulet, and Medtronic Diabetes; has received in-kind research support from Dexcom; and owns stock and shares with Supersapiens and Zucara Therapeutics. DPZ has received speaker's honoraria from Medtronic Diabetes, Ascensia Diabetes, and Insulet Canada, and research support from the Helmsley Charitable Trust and the International Society for Pediatric and Adolescent Diabetes Juvenile Diabetes Research Foundation Research Fellowship. JRC has served on advisory boards, data safety monitoring boards, or both, for Insulet, Novo Nordisk, and AstraZeneca, and owns stock in Pacific Diabetes Technologies; her institution, Oregon Health & Science University, has received research support from Dexcom. LMW, PGJ, and JCR time to write this Comment are supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (5R01DK120367-04).
PY - 2022/1
Y1 - 2022/1
UR - http://www.scopus.com/inward/record.url?scp=85121114157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121114157&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(21)00289-8
DO - 10.1016/S2213-8587(21)00289-8
M3 - Comment/debate
C2 - 34762835
AN - SCOPUS:85121114157
SN - 2213-8587
VL - 10
SP - 6
EP - 8
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 1
ER -